Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

The drug is expected to be available for commercial use in the U.S. in Q3 2025. AbbVie's stock currently trades near its 52-week high, with a year-to-date return of 9.6%. The company has maintained ...

ABBV) stands against the other stocks. Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald Trump’s recent actions and his effect on the stock market, urging investors ...

Several other research analysts have also recently commented on the stock. Daiwa Capital Markets cut shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. ABBV stock, with 24% returns ...

I think AbbVie is a fantastic stock to buy for income investors who also like some growth. The company is a Dividend King, with a high forward dividend yield of 3.5%. The stock is also reasonably ...